ExpreS2ion Biotechnologies ApS

ExpreS2ion Biotechnologies is a DK-based biotech company specialised in the development of new vaccines and immunotherapy products. The company has a discovery platform built around a proprietary protein manufacturing system, ExpreS2™, that is clinical Phase III-validated and is developed especially for fast and efficient development and production of complex proteins required for innovative new vaccines. The system also includes functionally modified glycosylation variants.

The Company employs a novel plug-&-play capsid virus-like particle (cVLP) platform, that offers competitive advantages in terms of long-term efficacy, safety, stability, and costing. The cVLP and ExpreS2™ platforms are basis for a proprietary HER2-cVLP breast cancer vaccine, ES2B-C001, which has compelling preclinical proof of concept, with completed GLP tox package, and is ready for CTA/IND initiation. 

The ExpreS2-only development pipeline includes four different malaria vaccine projects currently undergoing six different clinical Phase I and II studies (blood-stage malaria and transmission-blocking) sponsored by the academic partner University of Oxford. Furthermore, ExpreS2ion also develops novel influenza vaccines currently in preclinical development settings under non-diluting funding schemes. ExpreS2ion has a CMV vaccine-focused discovery collaboration with Evaxion Biotech A/S, a NASDAQ-listed Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. Most recently, in December 2023 ExpreS2ion was awarded a 100% non-dilutive Horizon Europe grant in a consortium aiming to develop a novel nipah virus vaccine candidate.

Since founded in 2010, ExpreS2ion has produced more than 500 proteins in collaboration with a high number of leading research institutions, biotech and pharma companies, demonstrating superior efficiency and success rates. The cVLP platform resides in the 34%-owned associate company AdaptVac ApS that was founded in 2017. 

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary and operational unit of ExpreS2ion Biotech Holding AB, listed on Nasdaq First North Growth Market, Stockholm (Ticker: EXPRS2).